|
|
Axsome Therapeutics Inc (AXSM) |
|
Price: $65.7700
$-0.49 
-0.740%
|
| Day's High:
| $67.2
| Week Perf:
| 11.14 %
|
| Day's Low: |
$ 64.67 |
30 Day Perf: |
5.94 % |
| Volume (M): |
741 |
52 Wk High: |
$ 91.29 |
| Volume (M$): |
$ 48,716 |
52 Wk Avg: |
$70.58 |
| Open: |
$66.33 |
52 Wk Low: |
$53.71 |
|
|
| Market Capitalization (Millions $) |
3,099 |
| Shares
Outstanding (Millions) |
47 |
| Employees |
48 |
| Revenues (TTM) (Millions $) |
223 |
| Net Income (TTM) (Millions $) |
-202 |
| Cash Flow (TTM) (Millions $) |
189 |
| Capital Exp. (TTM) (Millions $) |
1 |
Axsome Therapeutics Inc
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies for Central Nervous System (CNS) disorders, including depression, chronic pain, and other neurological conditions. Established in 2012, Axsome has its headquarters in New York, United States.
The company utilizes its proprietary technology and expertise to create novel treatment approaches that offer a new option for patients suffering from CNS disorders. Axsome's core competencies include drug discovery, preclinical and clinical development, and regulatory affairs. The company leverages its strengths and partnerships in these areas to accelerate the development of its therapeutic candidates.
Axsome's portfolio includes several product candidates that are either in the development or clinical testing stage. Some notable candidates include AXS-05, AXS-07, and AXS-1 AXS-05 is a combination of dextromethorphan and an inhibitor of the monoamine oxidase enzyme. This drug is being evaluated for the treatment of major depressive disorder and treatment-resistant depression. AXS-07 is a combination of an anti-inflammatory drug and a triptan, being developed for the treatment of migraines. AXS-12, on the other hand, is being developed for the treatment of narcolepsy.
Axsome has also been actively engaged in several partnership and licensing agreements to advance its pipeline of products. In 2018, the company signed a global license agreement for AXS-05 with Pfizer, which granted them rights to develop and commercialize this product in markets outside the United States. More recently, in 2021, Axsome signed a licensing agreement with Bausch Health that will allow the latter to manufacture and commercialize AXS-07 for migraines in Canada.
The company has been rapidly growing in the past few years, with its share price increasing considerably in response to positive clinical data and regulatory approvals. Axsome has also received several awards and recognitions for its innovative work, including being named as one of the top biotech companies to work for in 2021 by BioSpace.
In conclusion, Axsome Therapeutics Inc is a leading biopharmaceutical company that focuses on the development of innovative therapies for CNS disorders. The company has an extensive portfolio of product candidates, with several in various stages of development and clinical testing. Axsome has been recognized for its innovative work in the field of CNS disorders and has also been actively engaged in strategic partnerships to boost its progress. As the company's pipeline progresses, it has the potential to make a significant impact on the treatment of CNS disorders, particularly in areas where current treatment options are inadequate.
Company Address: One World Trade Center New York 10007 NY
Company Phone Number: 332-3241 Stock Exchange / Ticker: NASDAQ AXSM
| AXSM is expected to report next financial results on February 26, 2024. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Briacell Therapeutics Corp
The May to July 31, 2023 reporting season has resumed, and many companies, including those in the Major Pharmaceutical Preparations sector, have announced their financial numbers. Among these companies is Briacell Therapeutics Corp, which recently published an operating loss of $-7.705761 million for the financial fourth quarter of 2023. Additionally, Briacell Therapeutics Corp has reported a net deficit of $-14.300 million for the interval between May and July 31, 2023, which is a significant decline compared to the balanced books it maintained during the same period last year.
One noteworthy aspect is that the value of accounts receivable for Briacell Therapeutics Corp is still below the previous year's level; however, there has been some sequential progress. It is also important to mention that the company has observed a shortfall of $-20.30 million and has generated zero revenue during the financial period of 2023.
|
|
Gt Biopharma Inc
The stock market has always been a dynamic and exciting place, filled with ups and downs that keep investors on their toes. Today, we turn our attention to the Major Pharmaceutical Preparations industry and delve into the third quarter of 2023 numbers. Specifically, we examine Gt Biopharma Inc's financial report from July to September 30, 2023, which showcased an operating surplus of $3.122 million.
It's important to note that Gt Biopharma Inc has not cited any revenue yet, making the operating surplus even more impressive. As industry reporters analyze these figures, the prevailing situation of the organization becomes clearer. To truly understand the significance of the third quarter of 2023 earnings season, let's compare it with the same period in 2022.
|
|
Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals Inc, a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections, recently announced its financial results for the July to September 30, 2023, period. During this period, the company reported an increase in losses, which expanded from $1.27 per share a year prior to $1.32 per share. However, it is worth noting that the earnings per share (EPS) improved from -$1.86 in the preceding reporting period.
The revenue for the same period decreased by 6.817% to $18.93 million compared to $20.32 million in the previous reporting period. While sequentially, the revenue advanced slightly by 0.212% from $18.89 million. This decline in revenue could raise concerns, as it may indicate slowing demand for Enanta Pharmaceuticals Inc's products.
|
|
Procyon Corporation
Based on the financial time-frame ending September 30, 2023, Procyon Corporation has experienced significant declines and challenges, leading to a bearish outlook for the company. Depleting orders have played a crucial role in the losses incurred during this period.
The revenue for Procyon Corporation fell by -0.221% to $1.17 million compared to the previous reporting season, where revenue decreased by -2.42% from $1.20 million. This downward trend indicates a constant struggle for the company to maintain a steady revenue stream. It is clear that Procyon Corporation has been facing difficulties in generating consistent income.
|
|
China Health Industries Holdings Inc
China Health Industries Holdings Inc (CHHE) recently announced its financial results for the fiscal period ending September 30, 2023. These results demonstrate the company's ability to achieve top-line growth despite industry-wide revenue reductions. Additionally, CHHE's inventories have declined, indicating potential future demand. This article will outline the facts and set the current financial results into context.
Financial Results Overview:
For the fiscal period ending September 30, 2023, CHHE reported a zero gain of $0.00 per share, compared to a loss of $0.01 per share during the same period a year ago. Sequentially, CHHE improved from a loss of $0.01 per share in the previous quarter. This indicates progress in generating profits and more favorable financial performance.
|
| Per Share |
Current |
| Earnings (TTM) |
-4.41 $ |
| Revenues (TTM) |
4.74 $
|
| Cash Flow (TTM) |
4.01 $ |
| Cash |
8.84 $
|
| Book Value |
5.72 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-4.41 $
|
| Revenues (TTM) |
4.74 $ |
| Cash Flow (TTM) |
4.01 $ |
| Cash |
8.84 $
|
| Book Value |
5.72 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
